Evaluation of the clinical efficacy of asenapine in schizophrenia

Bibliography

• Perenyi A, Forlano R. Suicide in schizophrenia. Neuropsychopharmacol Hung 2005;7:107-17
   PubMedGoogle Scholar
• Casey DE, Haupt DW, Newcomer JW, Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004;65(Suppl 7):4-18
   PubMedGoogle Scholar
• Taylor DM. Prolongation of QTc interval and antipsychotics. Am J Psychiatry 2002;159:1062
   PubMedGoogle Scholar
• Carpenter WT, Buchanan RW. Lessons to take home from CATIE. Psychiatr Serv 2008;59:523-5
   PubMed Web of Science ®Google Scholar
• Parks J, Radke A, Parker G, Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr Bull 2009;35:931-6
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Pscyh 1996;153:321-30
   PubMed Web of Science ®Google Scholar
• Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry 2006;67(Suppl 9):3-8, discussion 36-42
   PubMed Web of Science ®Google Scholar
• Burstein ES, Ma J, Wong S, Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J Pharmacol Exp Ther 2005;315:1278-87
   PubMed Web of Science ®Google Scholar
• Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993;245:179-82
   PubMed Web of Science ®Google Scholar
• Taylor DM, Fischetti C, Sparshatt A, Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009;70:196-200
   PubMed Web of Science ®Google Scholar
• Citrome L. Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
   PubMed Web of Science ®Google Scholar
• Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-14
   PubMed Web of Science ®Google Scholar
• Marino J, Caballero J. Iloperidone for the treatment of schizophrenia. Ann Pharmacother 2010;44:863-70
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8:539-54
   PubMed Web of Science ®Google Scholar
• Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS drugs 2004;18:251-67
   PubMed Web of Science ®Google Scholar
• Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology 2008;200:317-31
   PubMed Web of Science ®Google Scholar
• Broekkamp CL, De Graaf JS, van Delft AM. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 1990;40:544-9
   PubMedGoogle Scholar
• Costall B, Domeney AM, Kelly ME, Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35:607-15
   PubMed Web of Science ®Google Scholar
• Franberg O, Wiker C, Marcus MM, Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology 2008;196:417-29
   PubMed Web of Science ®Google Scholar
• Marston HM, Young JW, Martin FD, Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology 2009;206:699-714
   PubMed Web of Science ®Google Scholar
• Funke CW, Hindriks H, Sam AP. Physico-chemical properties and stability of trans-5-chloro-2-methyl-2,3,3a, 12b-tetrahydro-1H- dibenz[2,3:6,7]oxepino[4,5-c]pyrrolidine maleate. Arzneimittelforschung 1990;40:536-9
   PubMed Web of Science ®Google Scholar
• Cosi C, Koek W. Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells. Eur J Pharmacol 2001;433:55-62
   PubMedGoogle Scholar
• Schotte A, Janssen PF, Gommeren W, Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 1996;124:87-94
   PubMed Web of Science ®Google Scholar
• Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39
   PubMed Web of Science ®Google Scholar
• Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharm 2009;23:65-73
   PubMed Web of Science ®Google Scholar
• Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68:2269-92
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Braff DL, Taaid N, Geyer MA. Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 1994;51:139-54
   PubMed Web of Science ®Google Scholar
• Schering-Plough. Saphris (Asenapine) sublingual tablets. Breifing document (Background Package). Schering-Plough Research Institute 2009
   Google Scholar
• Ellenbroek BA. Treatment of schizophrenia: a clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78
   PubMed Web of Science ®Google Scholar
• Geyer MA, Ellenbroek B. Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharm Biol Psychiatry 2003;27:1071-9
   PubMed Web of Science ®Google Scholar
• Moore NA, Leander JD, Benvenga MJ, Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997;58(Suppl 10):37-44
   PubMedGoogle Scholar
• Sun T, Hu G, Li M. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs. Eur J Pharmacol 2009;602:334-42
   PubMed Web of Science ®Google Scholar
• Swerdlow NR, Weber M, Qu Y, Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 2008;199:331-88
   PubMed Web of Science ®Google Scholar
• Barch DM, Carter CS, Arnsten A, Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull 2009;35:109-14
   PubMedGoogle Scholar
• Buchanan RW, Davis M, Goff D, A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Green MF, Kern RS, The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-13
   PubMed Web of Science ®Google Scholar
• Nuechterlein KH, Luck SJ, Lustig C, Sarter M. CNTRICS final task selection: control of attention. Schizophr Bull 2009;35:182-96
   PubMed Web of Science ®Google Scholar
• Young JW, Powell SB, Risbrough V, Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009;122:150-202
   PubMed Web of Science ®Google Scholar
• Potkin S, Fleming K, Binnerman B, Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Eur Neuropsychopharm 2007;17:S466-7
   Google Scholar
• Jentsch JD, Shahid M, Wong EHF, Roth RH. Asenapine improves cognitve function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine. Biol Psychiatry 2006;59(Suppl):471
   Google Scholar
• Neill JC, Shahid M, Grayson B, Asenapine improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat. Biol Psychiatry 2008;63(Suppl):75-6
   Google Scholar
• Neill JC, Shahid M, Wong EHF, Idris NF. Comparison of the efficacy of asenapine, risperidone, and olanzapine to improve a reversal learning deficit in the rat. Schizophr Res 2006;81(Suppl):105-6
   Google Scholar
• Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007;100:4-22
   PubMed Web of Science ®Google Scholar
• Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol 1999;9:301-9
   PubMed Web of Science ®Google Scholar
• Chapman S, Ragg M, McGeechan K. Citation bias in reported smoking prevalence in people with schizophrenia. Aust N Z J Psychiatry 2009;43:277-82
   PubMed Web of Science ®Google Scholar
• Schering-Plough. Full Prescribing Information: Saphris (asenapine). 2009
   Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63:1762-84
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68:1492-500
   PubMed Web of Science ®Google Scholar
• Curtis VA, Katsafouros K, Moller HJ, Long-acting risperidone improves negative symptoms in stable psychotic patients. J Psychopharm 2008;22:254-61
   PubMedGoogle Scholar
• Lane HY, Liu CC, Chang WH. Risperidone for exclusively negative symptoms. Am J Psychiatry 1999;156:335
   PubMedGoogle Scholar
• Riedel M, Spellmann I, Strassnig M, Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007;257:360-70
   PubMed Web of Science ®Google Scholar
• Kane JM, Cohen M, Zhao J, Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol 2010;30:106-15
   PubMed Web of Science ®Google Scholar
• Friberg LE, de Greef R, Kerbusch T, Karlsson MO. Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 2009;86:84-91
   PubMed Web of Science ®Google Scholar
• Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology 2004;174:17-24
   PubMed Web of Science ®Google Scholar
• Chapel S, Hutmacher MM, Haig G, Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49:1297-308
   PubMed Web of Science ®Google Scholar
• Schoemaker J, Naber D, Vrijland P, Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry 2010;43:138-46
   Google Scholar
• Weber J, McCormack PL. Asenapine. CNS Drugs 2009;23:781-92
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 2005;27:289-304
   PubMed Web of Science ®Google Scholar
• Choi YK, Wong EH, Henry B, Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol 2010;13:405-10
   PubMed Web of Science ®Google Scholar
• Tarazi FI, Choi YK, Gardner M, Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse 2009;63:413-20
   PubMed Web of Science ®Google Scholar
• Pfeiffer PN, Ganoczy D, Valenstein M. Dosing frequency and adherence to antipsychotic medications. Psychiatr Serv 2008;59:1207-10
   PubMed Web of Science ®Google Scholar
• Tait DS, Marston HM, Shahid M, Brown VJ. Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions. Psychopharmacology 2009;202:295-306
   PubMed Web of Science ®Google Scholar
• Ornstein TJ, Sahakian BJ, McKenna PJ. Memory and executive impairment in schizophrenia: comparison with frontal and temporal brain damage. Psychiatry Med 2008;38:833-42
   Google Scholar
• McIntyre RS, Cohen M, Zhao J, A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009;11:673-86
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cohen M, Zhao J, Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord 2009;11:815-26
   PubMed Web of Science ®Google Scholar